文献速递MDS 与骨髓增殖性肿瘤

Magrolimab联合阿扎胞苷对比安慰剂联合阿扎胞苷治疗初治高危骨髓增生异常综合征:III期ENHANCE研究

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.
PubMed 文献 · J Clin Oncol · 2026-07-13

ENHANCE研究是一项III期随机对照试验,纳入539例初治中危-2至极高危骨髓增生异常综合征患者,比较Magrolimab联合阿扎胞苷与安慰剂联合阿扎胞苷的疗效和安全性。Magrolimab联合组≥3级不良事件、导致停药的不良事件、严重不良事件及致死性不良事件发生率均更高。

要点

  • Magrolimab联合阿扎胞苷未改善完全缓解率(21.3% vs 23.6%)或总生存期(15.9 vs 18.6个月)。
  • Magrolimab联合组≥3级不良事件(92.8% vs 79.2%)及致死性不良事件(15.2% vs 9.8%)发生率更高。
  • 该方案不推荐用于初治高危MDS患者。

核心结论

  • ENHANCE研究未达到完全缓解率和总生存期双主要终点,且Magrolimab联合阿扎胞苷组严重不良事件更常见。

研究设计与样本

  • III期随机对照研究(ENHANCE,NCT04313881),共随机分配539例初治中危-2至极高危MDS患者至Magro/Aza组(n=268)或Placebo/Aza组(n=271)。

主要发现

  • ≥3级不良事件发生率:Magro/Aza组92.8% vs Placebo/Aza组79.2%。
  • 导致研究药物停药的不良事件发生率:Magro/Aza组24.0% vs Placebo/Aza组12.1%。
  • 严重不良事件发生率:Magro/Aza组71.9% vs Placebo/Aza组51.5%;致死性不良事件发生率:15.2% vs 9.8%。

关键数值与推荐

  • 完全缓解按2006年国际工作组标准评估。
  • Magro/Aza组给药方案:Magro第1、4天1 mg/kg,第8天15 mg/kg,第11、15天30 mg/kg,之后每周一次共5次,随后30 mg/kg每2周维持;Aza 75 mg/m2每日第1-7天或第1-5天及第8-9天,28天为一周期。
  • Placebo/Aza组接受匹配安慰剂联合相同阿扎胞苷方案。

临床怎么用

  • 对于初治高危MDS患者,不应在阿扎胞苷基础上联合Magrolimab,因未获益且毒性增加。
  • 临床决策应继续以阿扎胞苷单药为标准治疗之一,并关注不良事件管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of the cluster of differentiation 47-targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE study (ClinicalTrials.gov identifier: NCT04313881). METHODS: Based on the Revised International Prognostic Scoring System, patients with intermediate- to very-high-risk MDS were randomly assigned to receive Magro (1 mg/kg on days [D]1 and 4; 15 mg/kg on D8; 30 mg/kg on D11 and D15, and then once per week for five doses, followed by 30 mg/kg maintenance doses once every 2 weeks)/Aza (75 mg/m2 daily on D1-7 or on D1-5 and 8-9 in 28-day cycles) or matched placebo plus azacitidine (Placebo/Aza). Dual primary end points were complete remission (CR) rate (per 2006 International Working Group criteria) and overall survival (OS). RESULTS: At final analysis, 539 patients were randomly assigned to Magro/Aza (n = 268) or Placebo/Aza (n = 271) arms. Baseline characteristics were generally well balanced between treatment arms. In the Magro/Aza versus Placebo/Aza arms, the CR rate was 21.3% versus 23.6% (odds ratio, 0.876 [95% CI, 0.585 to 1.312]; P = .5218), and median OS was 15.9 versus 18.6 months (hazard ratio, 1.203 [95% CI, 0.947 to 1.528]; P = .1299). Magro/Aza had a higher incidence of grade ≥3 adverse events (AEs; 92.8% v 79.2%), AE-associated study drug discontinuations (24.0% v 12.1%), serious AEs (71.9% v 51.5%), and fatal AEs (15.2% v 9.8%) versus Placebo/Aza. CONCLUSION: ENHANCE did not meet the primary end points of CR rate and OS, and showed more frequent severe AEs in patients treated in the Magro/Aza arm.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sallman DA, Garcia-Manero G, Daver N, et al. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. J Clin Oncol. 2026. PMID: 42441929. doi:10.1200/JCO-25-00617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。